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Abstract 
Human induced pluripotent stem cells (iPSCs) offer a novel, timely approach for 
investigating the etiology of neuropsychiatric disorders. Although we are starting to 
gain more insight into the specific mechanisms that cause and 
other forms of dementia, this has not resulted in therapies to slow the pathological 
processes. Animal models have been paramount in studying the neurobiological 
processes underlying psychiatric disorders. Nonetheless, these human conditions 
cannot be entirely recapitulated in rodents. Human cell models 
cells now offer new hope for improving our understanding of the early molecular 
stages of these diseases, through to validating therapeutics. The impact of dementia 
is increasing, and a new model to investigate the early stages of this disease is 
heralded as an essential, new platform for translational research. In this article, we 
, describe drug 
discovery efforts using this platform, and discuss the future potential for this 
technology in psychiatry research.  
 
Animal models vs. human models 
 
The lack of predictive validity from preclinical animal studies for neuropsychiatric 
disorders is evidence of the need for new models in psychiatric research and 
neuroscience drug discovery to supplement these existing models (Markou et 
al., (AD) is an example of this, where the complex 
genetics is a major obstacle in successfully studying the disease. Established 
transgenic rodent models of AD have successfully recapitulated certain components 
of the neuropathology and cognitive deficits experienced by patients. However, even 
with known human AD mutations transgenic models do not exhibit all aspects of AD, 
such as extensive neuronal loss or distinct neurofibrillary tangle pathology (Duff, 
2001; Saraceno et al., 2013). Moreover, inserting the right genetic mutation may 
cause some extent of AD pathology, but it may still not be applicable to the majority 
of patients who have no known inherited mutations. Post mortem tissue and 
immortalised cell lines offer opportunities for studying the AD process in human 
tissue. Donated post mortem tissue may be the best way to study pathological 
features of the disease, but this is largely limited to looking at the end stage of the 
disease, it being difficult to access the brains of patients at earlier stages.  
 
Potential for human iPSCs in disease modelling 
 
Induced pluripotent stem cells (iPSCs) allow disease processes to be modelled for 
the first time in cells directly from patients. Adult somatic cell biopsies can be 
obtained, reprogrammed into iPSCs and then differentiated into the cell type of 
interest in vitro, as summarised in Figure 1. For disorders of the brain, where tissue 
from patients is inaccessible, iPSC technology offers the opportunity to study 
pathology as it develops in brain cells, whilst retaining the genetic background of the 
patient.  
 
The development of iPSCs was a game changing technology by Takahashi and 
Yamanaka, winning Yamanaka the Nobel Prize in Medicine in 2012. They 
demonstrated that adult somatic cells could be restored to a pluripotent state by 
transducing the cells in vitro with four transcription factors: Oct4, Sox2, Klf4, and c-
embryonic stem cells, mimic their morphology and growth properties, and can be 
differentiated into any specified cell type when in the presence of the molecular 
signals that would typically be present during development (Takahashi and 
Yamanaka, 2006).  
 
Human iPSC technology has offered a new way of studying human cells throughout 
disease development without the use of embryonic or immortalised cells. There are 
now numerous protocols for converting different cell types into stem cells, including 
cells that can be acquired relatively non-invasively such as keratinocytes or blood 
cells (Cocks et al., 2014). iPSCs can be passaged multiple times with minimal impact 
on genomic integrity and can be differentiated into, in theory, any cell type 
(Musunuru, 2013). Efficient protocols for cortical neurons based on developmental 
neurobiology studies are now well established and can produce neuronal cells with 
functional excitatory synapses, providing an unprecedented opportunity to develop 
live patient-specific models for disease in vitro. (Shi et al., 2012a; Zhang et al., 2013; 




Dementia is an age-related neurodegenerative disorder, characterised by cognitive 
, the most common type of dementia, accounts for 
up to 80% of all cases, with prevalence sharply increasing with age (Lobo et al., 
2000). AD is characterised by the presence of amyloid plaques, made up of -
amyloid ( ) protein aggregates, and neurofibrillary tangles, resulting from 
accumulated tau protein, in the brain. As with many central nervous system 
disorders, complex genetics of AD is still a major obstacle in successfully modelling 
the disease. A model based on cells derived from patients could be pivotal to 
determining relevant pathogenic mechanisms in humans. The excitement caused by 
this technological innovation is demonstrated by the rapid uptake of this system by 
the research 
and iPSCs growing steadily and the number of citations now over 2000 for all articles 
combined (Figure 2).  
 
Studies using neurons derived from iPSCs have already provided insights into 
mechanisms and evaluation of pre-clinical drugs (Bellin et al., 2012, Mertens et al., 
2013, Ross & Akimov, 2014). I  is secreted by neurons derived from 
patients with familial AD (fAD) mutations compared to cells from healthy controls in a 
period of weeks in vitro, despite this process taking years in humans in vivo (Yagi et 
al., 2011; Israel et al., 2012). iPSC-
with increased expression of the amyloid precursor protein (APP) gene on 
chromosome 21 also generated increased aggregates of 
intracellular and These neurons also presented a tau dysfunction 
phenotype, including abnormal tau localisation to the cell bodies and dendrites, and 
increased levels of total tau and two forms of phosphorylated tau (Shi et al., 2012b). 
Tau phenotypes have also been identified in lines from patients with mutations in the 
microtubule-associated protein tau (MAPT) gene. Neurons derived from patients with 
N279K showed changes in the 3R:4R tau isoform ratio and hyperphosphorylated tau 
aggregates, while neurons from P301L patients exhibited abnormal processes 
containing 4R tau (Iovino et al., 2015) 
 
Variability between patient lines has been reported in multiple studies, indicating 
difficulty in drawing conclusions about cellular processes in AD from a small number 
of iPSC lines. Some sporadic AD (sAD, or late-onset AD) lines did not show higher 
 in the neurons, and differences between intracellula
levels in patients with different APP mutations and sAD patient lines have also been 
described (Israel et al., 2012; Kondo et al., 2013). The complex interplay between 
genetic and environmental factors may mean that a large number of iPSC lines from 
sAD patients will be required to derive robust phenotypes.  
Protocols for human neural stem-cell-derived three-dimensional (3D) culture systems 
have been established that may support a more realistic cellular network and neural 
cell type representation, including GABAergic, glutamatergic, and dopaminergic 
neurons, as well as astrocytes and oligodendrocytes. The 3D neuronal cultures in 
this system exhibited 
aggregates of phosphorylated tau in the cell bodies of neurons differentiated from 
fAD iPSC lines (Choi et al., 2014). Therefore, these 3D culture systems will be of 
particular interest in recapitulating disease phenotypes, as the 2D in vitro models did 
not report aggregates of amyloid or tau protein, the characteristic hallmarks of AD in 




Neurons derived from iPSCs are now being utilised for drug screens to test for 
2011; 
Xu et al., 2013). Gamma secretase inhibitors were found to modulate the increased 
 found in fAD patients, and hence it may be beneficial to test the efficacy of 
compounds in -mediated toxicity in human neurons before 
clinical trials (Yagi et al., 2011). NSAID- -secretase modulators were tested in 
iPSC-derived neurons from AD patients, modulators that had previously lowered 
levels in various model systems but had translated poorly into human clinical trials. 
neurons to NSAID- -secretase modulation (Mertens et al.,2013). Another 
high-throughput revealed several small molecules that significantly 
blocked the toxic effects of  (Xu et al., 2013).  
 
These studies highlight the potential for iPSC models of AD as a pre-clinical tool for 
screening therapeutic compounds, testing early toxicity and efficacy, and developing 
a platform for drug development.Moreover, the advancement of this technology 
coincides with rapid progress in genetic techniques such as precise genome 
engineering and transcriptomic and proteomic analysis. The complement of these 
techniques could allow for human cells to model known pathogenic mutations in vitro, 
which could then be functionally validated and downstream targets could be 
confirmed. In the future these models could give rise to new preclinical model for 
drug discovery and even personalised therapeutics based on individuals genetics.  
 
Genome engineering in in vitro models 
 
Over the past decade, the field of genome editing has emerged whereby researchers 
can manipulate almost any gene in various cell types and organisms, through 
targeted cleavage of DNA. This is rapidly increasing our understanding of the genetic 
contribution of specific mutations to disease processes. Studies comparing iPSCs 
from patients with a monogenic disorder to healthy controls have not been able to 
account for differences in genetic background and epigenetic states of the iPSC 
lines. Precise genome editing allows for the specific effects of a mutation or gene to 
be studied in a cell line and the isogenic control. Correcting a single mutation, or 
creating one, removes all other variables, such as genetic alterations from 
reprogramming or irregularities with the epigenetic memory of an iPSC line 
(Musunuru, 2013).  
 
Precise genome engineering technologies, such as the CRISPR/Cas system, have 
provided a breakthrough in genome-editing technology. CRISPR/Cas enables 
specific mutations to be introduced with no off-target effects to the rest of the 
genome. iPSC lines with fAD mutations have been generated, displaying genotype-
dependent disease-associated phenotypes in the differentiated cortical neurons 
(Paquet et al., 2016). These cell lines are established from healthy controls, 
maintaining an identical genetic background in all lines. This technology facilitates 
the study of human disease by attributing certain phenotypes to specific genotypes, 
helping to decipher whether a single gene or a number of interacting genes is 
responsible for disease-associated phenotypes. 
 
Considerations in iPSC modelling 
 
The heterogeneity of iPSC lines due to variation in the genetic background of 
individuals is often discussed as a concern within the iPSC field. For example, Kondo 
et al. (2013) reported different phenotypes amongst cell lines from 4 AD patients (2 
sAD and 2 fAD). This has made it impossible to set guidleines for the number of 
patient and control lines that must be generated in order to validate specific clinical 
phenotypes in these models. Using fAD patients, in which a single mutation can 
cause a phenotype, reduces the number of lines required, however, cells from sAD 
patients may be more relevant to advancing the understanding of AD development in 
the majority of people living with dementia. In both these experimental designs the 
careful selection of gender and age-matched controls, including obtaining cells from 
unaffected siblings, can overcome such issues (Brennand et al., 2015; Santostefano 
et al., 2015). The generation of cell lines with disease-relevant mutations by genome 
editing methods also produces a perfect isogenic control, removing the need for 
numerous cell lines. A more general model for AD may be to treat wildtype neurons 
with exogenous , reducing the 
need for multiple control lines. However, this strategy also has issues due to the lack 
of consensus on the biophysical and biological behaviour of A  in vivo, and the 
instability Roychaudhuri et al., 
2009; Ryan et al., 2010). The different rates of  and tau production in iPSC-
derived neurons and the range of neuronal responses to  reflects the 
heterogeneity of patients with AD, and make iPSC models a representative tool for 
studying the multiple biological phenotypes of the disease.   
 
Another potential limitation for modelling disorders associated with ageing is the 
preservation of age in iPSCs reprogrammed from donors. Studies indicate that 
during reprogramming to an embryo-like iPSC state the original age of the somatic 
cells is lost (Lapasset et al., 2011, Meissner et al., 2008). The reprogramming phase 
resets many important hallmarks of ageing, including: extension of telomere length, 
restoration of mitochondrial function and reduced oxidative stress (Rohani et al., 
2014). iPSCs generated from donors aged 0 to 89 years did not retain ageing-
associated molecular signatures. However, the neurons they made directly from 
fibroblasts, induced neurons (iNs), preserved these signatures (Mertens et al., 2015). 
Therefore, iNs may be a useful technique in the future for modelling AD, and other 
diseases where ageing is an important risk factor, in vitro.  
 
The future of iPSC models in dementia 
 
One of the greatest aspects of iPSC-derived neurons is that they are generated from 
individuals, and so the disease process of patients with different genetic 
backgrounds can be investigated. This is interesting from the aspect of 
pharmacogenomics, where patients can be divided into subgroups, depending on 
factors such as sex and genotype, to identify successful treatments. This may be 
beneficial in heterogeneous neuropsychiatric disorders, such as AD, as drugs that 
have offered poor results in large trials may be effective in specific patient groups.  
 
Protocols for rapidly generating different glial cell types are emerging, together with 
3D cell cultures, providing more realistic in vitro systems incorporating cell types 
such as astrocytes and microglia that are known to be important in 
neurodegenerative disorders. Indeed, stem cell-derived neurons have increased 
synaptic activity in the presence of astrocytes (Johnson et al., 2007), and co-culture 
models could produce more relevant AD phenotypes. With genetic techniques rapidly 
advancing, iPSC-derived model systems allow risk mutations identified in dementia 
patients through genomics to be functionally validated. The human in vitro models 
discussed here with relevant AD pathologies offer hope for identifying novel 





In summary, iPSC technology offers a new method of studying the human brain and 
its pathologies, with exciting implications for basic research, as well as translational. 
iPSC modelling together with precise genome editing is already starting to 
complement existing models of psychiatric disorders and other human diseases. 
Cellular and molecular phenotypes can inform animal studies, and pathways from 
animal models can be confirmed in iPSC models. Human cell models could rapidly 
advance understanding of disease mechanisms, leading to potential therapeutics, 
and novel targets can undergo safety and efficacy testing in a human in vitro model 
prior to clinical trials. The revolutionary technologies described in this article could 
lead to the advancement in understanding of AD mechanisms and the refinement in 
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Figure 1. Adult somatic cells obtained from the root shaft of scalp hair are reprogrammed into iPSCs, which can then 
be differentiated into specific cell types. Cells from multiple sources can be utilised for reprogramming with the 
cytes providing a non-invasive option. iPSCs can be differentiated into any cell type, 
with the SMAD inhibition protocol developed by Shi et al. (2012a) producing cortical neurons. These neurons can be 
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